Immune-based approaches for control of HIV infection and viral-induced immunopathogenesis

Clinical Immunology

Volumn 97, Issue 1, 2000, Pages 1-8

  Pinto, Ligia A ^a   Shearer, Gene M ^a   Blazevic, Vesna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION CONTROL; INFECTION PREVENTION; LEUKOCYTE FUNCTION; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY;

EID: 0033800294     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4913     Document Type: Review

References (95)

1. + T cell homeostasis and function in advanced HIV disease
2. T cell regeneration in HIV-infected subjects under highly active antiretroviral therapy
3. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV- 1 infection
4. + T cell population with memory rather than naive cells
5. Changes in thymic function with age and during the treatment of HIV infection
6. + T cell responses associated with control of viremia
7. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
8. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
9. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
10. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
11. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
12. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
13. Latent reservoirs of HIV: Obstacles to the eradication of virus
14. Identification of a reservoir for HIV- 1 in patients on highly active antiretroviral therapy
15. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV- 1 immunogen
16. + cell numbers and clinical staging
17. + T helper cell depletion occurs
18. + memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals
19. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis
20. Mechanism of apoptosis in peripheral blood mononuclear cells of HIV-infected patients
21. T cell responses and viral escape
22. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin- 10 production
23. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness
24. Defective protein tyrosine phosphorylation and altered levels of p59fyn and p56lck in CD4 T cells from HIV- 1 infected patients
25. Human immunodeficiency virus infection abolishes CD4-dependent activation of ZAP- 70 by inhibition of p56lck
26. + lymphocytes from HIV-infected patients display impaired CD45-associated tyrosine phosphatase activity which is enhanced by anti-oxidants
27. 2+: Relationship to human immunodeficiency virus (HIV)-induced cellular hyporesponsiveness
28. + T lymphocytes
29. A TH1 → TH2 switch is a critical step in the etiology of HIV infection
30. Interleukin-10 gene expression induced by HIV-1 Tat and Rev in the cells of HIV- 1 infected individuals
31. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals
32. HIV- 1 infection induces a selective reduction in STAT5 protein expression
33. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
34. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens
35. 3
36. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
37. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
38. Host factors in the pathogenesis of HIV disease
39. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1
40. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV- 1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load
41. Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV- 1 infection
42. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
43. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response
44. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
45. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
46. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with nonprogressive infection
47. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type i infection
48. + T-cell-deficient mice
49. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice
50. In vivo migration and function of transferred HIV- 1-specific cytotoxic T cells
51. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
52. + lymphocytes
53. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death
54. Therapeutic vaccines in H.I.V. 1 infection
55. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV- 1 infection
56. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 phase II vaccine investigators
57. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD 4 cells
58. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals
59. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
60. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen
61. DNA vaccination with HIV- 1 expressing constructs elicits immune responses in humans
62. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
63. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines
64. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF- 2 recombinant vaccines in uninfected volunteers
65. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
66. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
67. Alloimmunization for immune-based therapy and vaccine design against HIV/ AIDS
68. Alloimmunization as an AIDS vaccine?
69. Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women
70. Alloantigen-stimulated anti-HIV activity
71. Alloantigen-induced anti-HIV activity occurs prior to reverse transcription and can be generated by leukocytes from HIV-infected individuals
72. Allostimulated lymphocytes inhibit replication of HIV type 1
73. Anti-cell antibody in macaques
74. Preliminary report: Protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine
75. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H
76. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type I transmission
77. Alloantigenic stimulation bypasses CD28-B7 costimulatory blockade by an interleukin-2 dependent mechanism
78. Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL- 2
79. Monocytes in HIV type 1-infected individuals lose expression of costimulatory B 7 molecules and acquire cytotoxic activity
80. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes
81. Direct gene transfer for the understanding and treatment of human disease
82. Inhibition of HIV- 1 replication prior to reverse transcription by influenza stimulation
83. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription
84. Suppression of HIV-1 transcription by beta-chemokines RANTES, MIP1-alpha, and MIP-1beta is not mediated by the NFAT- 1 enhancer element
85. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice
86. Human herpesvirus 6 inhibits human immunodeficiency virus type i replication in cell culture
87. Influenza A virus-induced IFN-alpha/beta and IL-18 synergistically enhance IFN-gamma gene expression in human T cells
88. Role of interleukin- 12 in primary influenza virus infection
89. Regulation of the IL-12/IL-12R axis: A critical step in T-helper cell differentiation and effector function
90. Cytokine profiles in HIV type 1 disease and protection
91. Circumvention of defective CD4 T helper cell function in HIV-infected individuals by stimulation with HLA alloantigens
92. + T-helper and a T-killer cell
93. Viruses as immunological adjuvants in cancer
94. Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer
95. + T cell response to HIV- 1 env by combined immunization with influenza and vaccinia virus recombinants